South Korea’s Research Investment for Global Health Technology (RIGHT) Fund launched its sixth RFP on Monday: a new Technical Accelerator Award granting up to $440,000 (per project, for up to one year) for “original and innovative concepts” that tackle endemic and emerging infectious diseases in developing countries.
Applicants must include at least one Korean entity. Proposals for vaccines and therapeutics are due by April 9 and for diagnostics and digital health by April 30.
South Korea’s Research Investment for Global Health Technology (RIGHT) Fund launched a new RFP this week, awarding up to $452,000 (per grant) for early-stage vaccines, therapeutics, diagnostics and digital health technology projects tackling infectious diseases in developing countries.
Applicants must include at least one Korean entity and submit their proposals by December 18. RIGHT Fund has so far invested $25.3 million in 22 R&D projects since its launch, according to the press…
The state of the hunt:
Novavax brought its vaccine candidate to Phase 2.
Vaccines
Phase 3 candidates:
Pfizer and BioNTech have enrolled more than half of the 30,000 people they seek for U.S.-based Phase 3 trials of their mRNA Covid-19 vaccine candidate,…
South Korea’s Research Investment for Global Health Technology (RIGHT) Fund announced this week an additional $14.9 million for 17 infectious disease projects, including Covid-19 vaccines and technology.
The fund said it has now committed approximately one-third of its investment portfolio to respiratory infections since its launch in 2018.
The fund’s RFP for R&D projects is open through July 6.
South Korea’s Research Investment for Global Health Technology (RIGHT) Fund launched a new RFP today, calling for “mid-to-large project” proposals for vaccines, therapeutics, diagnostics and digital health technology tackling infectious diseases in developing countries. The RFP also includes projects to combat Covid-19.
South Korea’s Research Investment for Global Health Technology (RIGHT) Fund launched a new Technical Accelerator Award last week, calling for early-stage research proposals for infectious diseases for which “there are no available therapeutics, vaccines or diagnostics options,” including Covid-19.
Founded in July 2018, the RIGHT Fund—with $39.8 million in available funding through 2022—is a public-private partnership between Korea’s health ministry, the Gates Foundation, and Korean…
Korea’s Research Investment for Global Health Technology (RIGHT) Fund announced its first four recipients of $5.8 million in grants last week at its 2019 investment forum.
EuBiologics (with Seoul’s International Vaccine Institute, Massachusetts General Hospital and Harvard Medical School) won support for its preclinical cholera conjugate vaccine.
SK Biotek (with the Medicines for Malaria Venture) will get funding for continuous process development and scale-up of new malaria…